氟替美维吸入粉雾剂(Trelegy Ellipta)的用法用量:用药指南,剂量调整,特殊人群用药

Flutimavir inhalation powder spray (TrelegyEllipta) is only for oral inhalation. The specific usage and dosage must be strictly followed by your doctor's advice.

Usage and Dosage of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. Administration Method

Inhale 1 spray of Flutimavir Inhalation Powder Aerosol by mouth once a day.

After inhalation, rinse your mouth with water without swallowing to help reduce the risk of candida infection in the oropharynx.

Should be used at the same time every day. Do not use more than once every 24 hours.

2. Recommended dosage for maintenance treatment of chronic obstructive pulmonary disease

The recommended dosage of flutimevir inhalation powder for maintenance treatment of chronic obstructive pulmonary disease is fluticasone furoate 100mcg, umeclidinium bromide 62.5mcg and vilanterol 25mcg (flutimevir inhalation powder 100/62.5/25mcg 1 spray), once daily by oral inhalation.

Flutimavir inhalation powder 100/62.5/25mcg is the only specification suitable for the treatment of chronic obstructive pulmonary disease.

3. Recommended dosage for asthma maintenance treatment

The recommended starting dose of fluticasone furoate 100mcg, umeclidinium bromide 62.5mcg and vilanterol 25mcg (flutimevir inhalation powder) for asthma maintenance treatment Inhalation powder spray 100/62.5/25mcg 1 spray) or fluticasone furoate 200mcg, umeclidinium bromide 62.5mcg and vilanterol 25mcg (flutimavir inhalation powder spray 200/62.5/25mcg 1 spray), inhaled orally once a day.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Dose adjustment of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. The maximum recommended dose is Flutimavir Inhalation Powder Aerosol 200/62.5/25mcg once daily.

2. For patients who do not respond well to flutimavir inhalation powder spray 100/62.5/25mcg once daily, increasing the dose to flutimavir inhalation powder spray 200/62.5/25mcg once daily may provide additional improvements in asthma control.

3. For patients who have poor response to once-daily flutimavir inhalation powder spray 200/62.5/25mcg, other treatment options and additional treatment options should be re-evaluated and considered.

4. If asthma symptoms occur during two treatments, an inhaled short-acting β2-receptor agonist (rescue drug, such as albuterol) should be used for immediate relief.

Dose adjustment of flutimavir inhalation powder (Trelegy Ellipta) for special groups

No dose adjustment is required for elderly patients, patients with renal impairment or patients with moderate liver impairment.

Usage of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta) in Special Populations

1. Pregnancy

There are insufficient data on the use of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta) or its individual components (fluticasone furoate, umeclidinium bromide, and vilanterol) in pregnant women to inform drug-related risks.

2. Lactation

There is no information on the presence of flutimavir inhalation powder in human milk, nor on the effects on breastfed children or on milk production.

The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for fluticasone furoate, umeclidinium, or vilanterol or the underlying maternal condition in the breastfed child.

3. Pediatric use

The safety and effectiveness of flutemevir inhalation powder have not been established in pediatric patients (17 years and younger), and flutemevir inhalation powder is not intended for use in pediatric patients.

4. Medication for the elderly

Elderly patients do not need to adjust the dose of flutimavir inhalation powder, but it cannot be ruled out that some elderly individuals are more sensitive.

5. Hepatic Impairment

Flutimevir inhalation powder has not been studied in subjects with hepatic impairment.

6. Renal impairment

Flutimavir inhalation powder has not been studied in subjects with renal impairment.